Navigation Links
Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
Date:1/26/2009

lesser extent, loss of segment share. International Aranesp sales decreased 5 percent to $345 million versus $365 million in the fourth quarter of 2007 due to changes in foreign exchange which negatively impacted fourth quarter 2008 sales by approximately $12 million, pricing pressure, and ESA (erythropoiesis stimulating agent) dosing conservatism in our oncology business. Excluding the impact of foreign exchange, worldwide product sales decreased 13 percent and international product sales decreased 2 percent. For the full year, worldwide Aranesp sales were $3,137 million in 2008 versus $3,614 million in 2007, a 13 percent decrease. This decrease in sales was primarily due to a decline in demand reflecting reaction to regulatory and reimbursement developments and, to a lesser extent, loss of segment share noted above.

Sales of EPOGEN(R) (Epoetin alfa) increased 1 percent to $646 million in the fourth quarter of 2008 versus $638 million in the fourth quarter of 2007, primarily due to favorable changes in wholesaler inventories, partially offset by a decline in demand and to a lesser degree spillover. The decline in demand is principally due to a decline in the average net sales price and lighter year end customer demand, partially offset by an increase in patient population growth. For the full year, EPOGEN sales were $2,456 million in 2008 versus $2,489 million in 2007, a 1 percent decrease. This decrease in sales is principally due to a slight decline in demand. Spillover is a result of the Company's contractual relationship with Johnson & Johnson. (Please refer to the Company's Form 10-K for a more detailed discussion of this relationship and a description of spillover).

Combined worldwide sales of Neulasta(R) (pegfilgrastim) and NEUPOGEN(R) (Filgrastim) increased 6 percent to $1,180 million in the fourth quarter of 2008 versus $1,118 million for the fourth quarter of 2007, driven primarily by increased demand for Neu
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Beckman Coulter Announces Fourth Quarter 2008 Earnings to be Released on Monday, February 9, 2009, After Market Closes
2. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
3. Caliper Life Sciences Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
4. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
5. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
6. BioMed Realty Trust Declares Fourth Quarter 2008 Common Stock and Preferred Stock Dividends
7. Martek Announces Fourth Quarter and FY 2008 Financial Results
8. Martek to Announce Fourth Quarter and Fiscal Year 2008 Results
9. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year
11. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... A recent study from researchers in Tasmania ... that those who took probiotics were able to run for ... showed that in extreme heat conditions, probiotics were able to ... acne treatment explains what this new discovery means for ... skin condition. , While researchers tote the benefits of ...
(Date:5/21/2013)... YORK , May 21, 2013  The Lindsley F. ... today that it is a Grand Challenges Explorations ... Gates Foundation .  Dr. Sara Lustigman , ... innovative global health and development research project, titled Innovative ...  These worms are needed to screen drugs to help ...
(Date:5/21/2013)... 2013 The congress of the ... is the biggest congress in Europe ... participants are in Istanbul to ... New pioneering studies have been presented: / ... ADMINISTERED VIA HEMODIALYSATE REDUCES ESA USE" By ...
(Date:5/21/2013)... May 21, 2013 As the ... strong push within the industry to deliver better ... Organizations and pharma companies often means turning big ... Microtablets, developed in collaboration with Sensidose AB and ... can bring products to market sooner. The partnership ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2
... Therapeutics Inc.,(Lorus), a biopharmaceutical company specializing in the research ... cancer, today reported financial results for the three and ... amounts are in Canadian,dollars., 2008 HIGHLIGHTS, ... Lorus, lead anticancer small ...
... N.J., July 21 Schering-Plough,Corporation (NYSE: SGP ... call and,webcast to review the sales and earnings ... p.m. (EDT) from 8 a.m. today. The quarterly,financial ... after the close of,the New York Stock Exchange., ...
... Limited (TSX: GEN),a company focused on developing ... diseases and personalized health management, today announced,the ... molecular test,for colorectal cancer screening. ColonSentry(TM) is ... risk of having colorectal cancer, identifying,those in ...
Cached Biology Technology:Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 2Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 3Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 4Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 5Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 6Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 7Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008 8Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today 2GeneNews launches world's first blood test for colorectal cancer screening 2GeneNews launches world's first blood test for colorectal cancer screening 3
(Date:5/21/2013)... Cancers of all types become most deadly when ... cancer has reached this stage, it becomes very difficult ... that can develop. Now, researchers at the University of ... that target lymphoma tumor cells wherever they may be ... oncology in the MU College of Veterinary Medicine, says ...
(Date:5/21/2013)... the world,s largest scientific society, invites news media ... September 8-12, 2013, in Indianapolis, Ind. It will ... at area hotels. , With more than 7,100 ... from astronomy to zoology ― the meeting ... rich assortment of spot news and feature possibilities. ...
(Date:5/21/2013)... genes function without changing the underlying DNA sequence, ... pregnant women during any trimester, potentially providing a ... after giving birth, and an opportunity to intervene ... the small study involving 52 pregnant women are ... . , "Postpartum depression can be harmful to ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3
... CA] A new study, led by PRBO Conservation Science ... marshes under high-end sea-level rise scenarios that are increasingly likely. ... scenario 93% of San Francisco Bay,s tidal marsh could be ... 1.65 meters of sea-level rise, low sediment availability and no ...
... centuries that many bacteria produce hydrogen sulfide (H2S) it was ... Now, researchers at NYU School of Medicine have discovered ... from the effects of numerous different antibiotics. In ... Anderson Professor of Biochemistry at NYU School of Medicine, researchers ...
... BLACKSBURG, VA -- Many landscape trees are started in-ground, ... them in large containers to grow. To minimize wind ... growing beds, the liners are often buried deeper than ... container plants with deep structural roots, important foundations of ...
Cached Biology News:Bleak future for Bay area tidal marshes? 2Bleak future for Bay area tidal marshes? 3Bleak future for Bay area tidal marshes? 4Targeting bacterial gas defenses allow for increased efficacy of numerous antibiotics 2Planting depth's effect on container-grown trees 2
... The loxP-cm-loxP cassette ... in prokaryotic cells. The prokaryotic ... chloramphenicol resistance is a slightly modified ... mediates higher transcription efficiency than the ...
... Agencourt AMPure is a magnetic ... requires no sample transfer, centrifugation ... purifies small and large PCR ... 384-well microplates. Agencourt AMPure can ...
... a magnetic bead-based PCR purification ... transfer, centrifugation or filtration steps. ... large PCR extension products in ... AMPure can easily be performed ...
Kit includes your choice of reagents for labeling 3 x 10 9 cells and EasySep magnet....
Biology Products: